Collegium to Present at Upcoming Investor Conferences

CANTON, Mass., Sept. 06, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in September:

• The 19^th Annual Rodman & Renshaw Global Investment Conference on Monday, September 11^th at 12:05 p.m. ET at the Lotte New York Palace Hotel
• The Cantor Fitzgerald Global Healthcare Conference on Monday, September 25^th at 4:45 p.m. ET at the InterContinental New York Barclay Hotel

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx^® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact: 
Alex Dasalla
[email protected]